Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Stephen V Liu, MD
Georgetown University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Rain-701 Study Site
Toronto, Ontario, Canada
- Rain-701 Study Site
Hong Kong, Hong Kong
- Hong Kong United Oncology Center
Kowloon, Hong Kong
- Rain-701 Study Site
Irvine, California, United States
- Pacific Shores Medical Group
Long Beach, California, United States
- University of California San Francisco, Helen Diller Cancer Center
San Francisco, California, United States
- Rain-701 Study Site
Aurora, Colorado, United States
- Georgetown University Medical Center
Washington D.C., District of Columbia, United States
- Comprehensive Care and Research Center, Atlanta
Newnan, Georgia, United States
- Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
- Henry Ford Cancer Institute
Detroit, Michigan, United States
- Providence Cancer Institute
Portland, Oregon, United States
- Rain-701 Study Site
Pittsburgh, Pennsylvania, United States
- Rain-701 Study Site
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 13 Mar 2019
- Primary completion
- 9 Apr 2021
- Completion
- 23 Apr 2021
- Last update posted
- 28 Jun 2023
- Registered enrollment
- 41
- Registry id
- NCT03805841
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.